<jck class="ceurgu"></jck>

南宫NG28

Company Updates

Four-Party Strategic Agreement! Hemogen and Mahidol University Join Forces to Advance Thalassemia Gene Therapy in Thailand

On July 18th, Dr. Chao Liu, CEO of Hemogen, Mr. Preecha Laohapongchana, Director of Xingtai Genetics, Dr. Apichat Asavamongkolkul, Dean of the Faculty...

World Thalassemia Day | Hemogen Joins Hands with You to Build a World Free from Thalassemia

May 8, 2023 marks the 30th World Thalassemia Day. In order to further improve the prevention and treatment of Mediterranean anemia (hereinafter referr...

Global First: α-Thalassemia Patient Successfully Freed from Blood Transfusion Dependence through Gene Therapy!

On February 10, 2023, Hemogen Theropeutic Co.Ltd (Hemogen, a subsidiary of BGI), Thalassemia Diagnosis and Treatment Innovation Research Center of Nan...

ONE BGI: Hemogen Visits the Middle East and Southeast Asia, Initiating Overseas Implementation of " Creating A Thalassemia-Free World Together "

The Middle East and Southeast Asia are high-prevalence areas for thalassemia and sickle cell anemia as well as significant regions along Belt and Road...

The kick-off meeting of “HGI-002 Injection (Treatment of α-Thalassemia)” was successfully held!

Shenzhen Hemogen Therapeutics Co., Ltd. (hereinafter referred to as: HGI) cooperated with department of hematology of 923 Hospital on the topic of “Cl...

HGI-001 Injection" clinical research (β-thalassemia) kick-off meeting was successfully held!

The kick-off meeting of "HGI-001 Injection" in cooperation with Shenzhen University General Hospital was held successfully on November 15th,...

BGI group gives hope to transfusion-dependent thalassemia (TDT) patients and their families

Dasai and his sister are from a small village in Guangxi Province. They are both diagnosed with transfusion-dependent thalassemia (TDT). Unfortunatel...

Previous 1 2 Next

info@thg66.com